Breaking Down Moderna: 7 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Over the past three months, 7 analysts have shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks. The average 12-month price target has increased to $132.14. Analysts have recently adjusted their ratings and price targets, reflecting their responses to Moderna's market performance and financial indicators.
June 03, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have diverse outlooks on Moderna, with recent ratings showing a mix of 'Buy', 'Hold', and 'Outperform'. The average 12-month price target has increased to $132.14, indicating a positive sentiment shift. However, financial indicators such as revenue growth, net margin, ROE, and ROA are below industry standards.
The increase in the average 12-month price target to $132.14 suggests a positive sentiment shift among analysts. However, financial indicators such as revenue growth, net margin, ROE, and ROA being below industry standards may temper short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100